Retrospective Study of Implants With Peri-implantitis Surgically Treated Using Enamel Matrix Derivative (EMD)

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT05419102

Enrollment

Registered

2022-06-15

Start date

2022-04-01

Completion date

2022-06-06

Last updated

2022-06-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Determination of Beneficial Effect of Using Enamel Matrix Derivative During Implant Treatment

Keywords

dental implant, peri-implantitis, enamel matrix derivative

Brief summary

The existing records of a private practice limited to the practice of periodontology were reviewed to locate patients who had been diagnosed with peri-implantitis (failing dental implant) and had been surgically treated utilizing enamel matrix derivative (Commercially available FDA product Emdogain sold by Straumann USA). Various clinical factors were gathered from the existing records. Some of the factors recorded were: retention of the implant, presence of bleeding, presence of further damage, and presence of inflammation. All patients had signed an informed consent for treatment and the anonymous use of their data for research purposes. All HIPA requirements were followed.

Detailed description

See brief summary.

Interventions

PROCEDUREperi-implantitis surgery with enamel matrix derivative

surgical procedures around dental implants with peri-implantits to remove infectious material and apply enamel matrix derivative to the implant.

Study design

Observational model

COHORT

Time perspective

OTHER

Eligibility

Sex/Gender

ALL

Age

18 Years to 90 Years

Healthy volunteers

Inclusion criteria

* all adult patients of record who presented with existing peri-implantitis that was clinically deemed treatable (the implant was not considered hopeless.)

Exclusion criteria

* none except for routine medical contraindications for periodontal surgery

Design outcomes

Primary

Measure	Time frame	Description
retention of the implant	0.71 to 6.4 years	Determine if the implant was still present at the time of reevaluation

Secondary

Measure	Time frame	Description
record the clinical condition of the implant at the time of reevaluation	0.71 to 6.4 years	Multiple standard measurements of the clinical condition of the implant were recorded at the time of reevaluation

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026